- Home
- SKWD vs CGON Comparison
SKWD vs CGON Comparison
Compare SKWD & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKWD
- CGON
- Stock Information
- Founded
- SKWD 2007
- CGON 2010
- Country
- SKWD United States
- CGON United States
- Employees
- SKWD N/A
- CGON N/A
- Industry
- SKWD Property-Casualty Insurers
- CGON
- Sector
- SKWD Finance
- CGON
- Exchange
- SKWD Nasdaq
- CGON NYSE
- Market Cap
- SKWD 2.4B
- CGON 2.1B
- IPO Year
- SKWD 2023
- CGON 2024
- Fundamental
- Price
- SKWD $55.06
- CGON $27.03
- Analyst Decision
- SKWD Buy
- CGON Strong Buy
- Analyst Count
- SKWD 12
- CGON 10
- Target Price
- SKWD $63.88
- CGON $64.44
- AVG Volume (30 Days)
- SKWD 408.5K
- CGON 839.6K
- Earning Date
- SKWD 08-04-2025
- CGON 08-07-2025
- Dividend Yield
- SKWD N/A
- CGON N/A
- EPS Growth
- SKWD 9.29
- CGON N/A
- EPS
- SKWD 2.98
- CGON N/A
- Revenue
- SKWD $1,213,759,000.00
- CGON $662,000.00
- Revenue This Year
- SKWD $18.33
- CGON N/A
- Revenue Next Year
- SKWD $11.61
- CGON $25,206.93
- P/E Ratio
- SKWD $18.40
- CGON N/A
- Revenue Growth
- SKWD 26.30
- CGON 224.51
- 52 Week Low
- SKWD $34.10
- CGON $14.80
- 52 Week High
- SKWD $65.05
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- SKWD 37.51
- CGON 59.29
- Support Level
- SKWD $53.27
- CGON $25.51
- Resistance Level
- SKWD $58.18
- CGON $27.28
- Average True Range (ATR)
- SKWD 1.67
- CGON 1.01
- MACD
- SKWD -0.43
- CGON 0.02
- Stochastic Oscillator
- SKWD 26.64
- CGON 89.23
About SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.